| Recruiting | Study for Turoctocog Alfa Treatment Regimen in Iraqi Haemophilia A Patients NCT06574984 | Novo Nordisk A/S | — |
| Completed | Study Investigating Novoeight®/NovoEight® (Turoctocog Alfa) in Mexican Haemophilia A Patients NCT03179748 | Novo Nordisk A/S | — |
| Completed | A Research Study Looking at How a Factor VIII Medicine Called Turoctocog Alfa Pegol (N8-GP) Works in People Wi NCT03528551 | Novo Nordisk A/S | Phase 3 |
| Completed | Research Study to Look at Side Effects During Regular Injection With Factor VIII Medicine Named Turoctocog Alf NCT03449342 | Novo Nordisk A/S | Phase 4 |
| Completed | A Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B NCT03196284 | Novo Nordisk A/S | Phase 2 |
| Completed | A Trial Comparing Nonacog Beta Pegol (N9-GP) and ALPROLIX® in Patients With Haemophilia B NCT03075670 | Novo Nordisk A/S | Phase 1 |
| Completed | Safety, Tolerability, and Pharmacokinetics Study of Turoctocog Alfa Pegol Injected Under the Skin in Patients NCT02994407 | Novo Nordisk A/S | Phase 1 |
| Completed | Efficacy and Safety of Turoctocog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treate NCT02938585 | Novo Nordisk A/S | Phase 3 |
| Completed | Evaluating the Pharmacokinetics of NovoEight® (Turoctocog Alfa) in Relation to BMI in Subjects With Haemophili NCT02941354 | Novo Nordisk A/S | Phase 1 |
| Completed | A Multi-centre, Comparative, Double Blind, Randomised Cross-over Trial Investigating Single Dose Pharmacokinet NCT02920398 | Novo Nordisk A/S | Phase 1 |
| Completed | A Study of Safety and Effectiveness of NovoThirteen® (rFXIII) During Treatment of Congenital FXIII Deficiency NCT02670213 | Novo Nordisk A/S | — |
| Completed | Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to NCT02490787 | Novo Nordisk A/S | Phase 1 |
| Completed | Bridging Hemophilia B Experiences, Results and Opportunities Into Solutions (B-HERO-S) NCT02568202 | Novo Nordisk A/S | — |
| Completed | Pharmacogenetic Testing of Saliva Samples From Patients With Five or More Exposure Days to rFVIIa Analogue in NCT02541942 | Novo Nordisk A/S | Phase 2 |
| Completed | To Quantify the Range of Main Psychosocial Factors Affecting Patients and Caregivers in Their Daily Lives NCT02241694 | Novo Nordisk A/S | — |
| Completed | A Study to Evaluate Safety and Efficacy of NovoSeven® in Patients With Glanzmann's Thrombasthenia in Japan NCT01876745 | Novo Nordisk A/S | — |
| Completed | To Investigate Safety and Efficacy of NovoEight® (rFVIII) During Long-term Treatment of Haemophilia A in Japan NCT02207218 | Novo Nordisk A/S | — |
| Completed | Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated Patients With Haemophilia B NCT02141074 | Novo Nordisk A/S | Phase 3 |
| Completed | Safety and Efficacy of Turoctocog Alfa Pegol (N8-GP) in Previously Untreated Patients With Haemophilia A NCT02137850 | Novo Nordisk A/S | Phase 3 |
| Completed | Safety and Efficacy of Turoctocog Alfa During Long-Term Treatment of Severe and Moderately Severe Haemophilia NCT02035384 | Novo Nordisk A/S | — |
| Completed | Project to Update the Study of Congenital Haemophilia in Spain NCT01959555 | Novo Nordisk A/S | — |
| Withdrawn | Investigating the Bioequivalence of Eptacog Alfa A 6 mg and NovoSeven® in Healthy Male Subjects NCT02084810 | Novo Nordisk A/S | Phase 1 |
| Completed | Impact of Pain on Functional Impairment and Quality of Life in Adults With Hemophilia NCT01988532 | Novo Nordisk A/S | — |
| Completed | A Trial Investigating the Pharmacokinetics and Pharmacodynamics of rFVIIa in Patients With Haemophilia A or B NCT01949792 | Novo Nordisk A/S | Phase 1 |
| Completed | Use of rFXIII in Treatment of Congenital FXIII Deficiency, a Prospective Multi-centre Observational Study NCT01862367 | Novo Nordisk A/S | — |
| Completed | A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-10 NCT01731600 | Novo Nordisk A/S | Phase 3 |
| Completed | Investigation of the Pharmacokinetics of Turoctocog Alfa in Subjects With Haemophilia A NCT01692925 | Novo Nordisk A/S | Phase 1 |
| Completed | Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children NCT01493778 | Novo Nordisk A/S | Phase 3 |
| Completed | Evaluating the Haemostatic Effect of NNC 0129-0000-1003 During Surgical Procedures in Subjects With Haemophili NCT01489111 | Novo Nordisk A/S | Phase 3 |
| Terminated | A Multi-centre, Open Labelled, Multiple Dosing Trial Investigating Safety, Pharmacokinetics and Pharmacodynami NCT01631942 | Novo Nordisk A/S | Phase 1 |
| Completed | Efficacy and Safety of NNC-0156-0000-0009 During Surgical Procedures in Subjects With Haemophilia B NCT01386528 | Novo Nordisk A/S | Phase 3 |
| Completed | Safety, Efficacy and Pharmacokinetics of NNC-0156-0000-0009 in Previously Treated Children With Haemophilia B. NCT01467427 | Novo Nordisk A/S | Phase 3 |
| Completed | Safety and Efficacy of NNC-0156-0000-0009 After Long-Term Exposure in Patients With Haemophilia B: An Extensio NCT01395810 | Novo Nordisk A/S | Phase 3 |
| Completed | Investigation of the Pharmacokinetics of NNC172-2021, at Two Different Dose Levels, in Healthy Japanese Subjec NCT01555749 | Novo Nordisk A/S | Phase 1 |
| Completed | Evaluation of Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Tre NCT01480180 | Novo Nordisk A/S | Phase 3 |
| Completed | Epidemiological Study on Haemophilia Care and Orthopaedic Status in Developing Countries NCT01503567 | Novo Nordisk A/S | — |
| Completed | Efficacy and Safety of NNC 0078-0000-0007 in Patients With Congenital Haemophilia and Inhibitors NCT01392547 | Novo Nordisk A/S | Phase 3 |
| Completed | Survey Evaluating the Psychosocial Effects of Living With Haemophilia NCT01322620 | Novo Nordisk A/S | — |
| Completed | A Single Dose Trial of NNC 0155-0000-0004 in Patients With Haemophilia A NCT01365520 | Novo Nordisk A/S | Phase 1 |
| Completed | Safety and Efficacy of NNC-0156-0000-0009 in Haemophilia B Patients NCT01333111 | Novo Nordisk A/S | Phase 3 |
| Completed | A Long-term Assessment of Physical Activity, Range of Motion, and Functional Status Following Elective Orthope NCT01830712 | Novo Nordisk A/S | — |
| Completed | Observational Study on Safety and Efficacy of NovoSeven® in Subjects With Congenital FVII Deficiency NCT01312636 | Novo Nordisk A/S | — |
| Completed | Investigating Safety and Pharmacokinetics of NNC 0128-0000-2011 Compared to NNC 0128-0000-2021 in Healthy Male NCT01272206 | Novo Nordisk A/S | Phase 1 |
| Completed | Investigating Safety and Pharmacokinetics of 2 Different Single Doses of NNC128-0000-2011 in Haemophilia A or NCT01288391 | Novo Nordisk A/S | Phase 1 |
| Completed | Safety and Efficacy of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Paediatric Subject NCT01253811 | Novo Nordisk A/S | Phase 3 |
| Completed | Observational Study on Safety of Room Temperature Stable NovoSeven® in Patients With Haemophilia A or B NCT01220141 | Novo Nordisk A/S | — |
| Completed | A Single Dose Trial of Recombinant Factor VIII (N8) in Japanese Subjects With Haemophilia A: An Extension to T NCT01238367 | Novo Nordisk A/S | Phase 1 |
| Completed | Safety of a Single Intravenous Dose of Recombinant Factor XIII in Children With Congenital FXIII A-subunit Def NCT01230021 | Novo Nordisk A/S | Phase 3 |
| Completed | Safety of NNC 0172-0000-2021 in Healthy Male Subjects and Subjects With Haemophilia A or B NCT01228669 | Novo Nordisk A/S | Phase 1 |
| Completed | Observational Study Describing the Usual Clinical Practice Use of NovoSeven® in the Home Treatment of Joint Bl NCT01234545 | Novo Nordisk A/S | — |
| Completed | Safety and Pharmacokinetics of NNC 0129-0000-1003 in Subjects With Haemophilia A NCT01205724 | Novo Nordisk A/S | Phase 1 |
| Completed | Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia A NCT01138501 | Novo Nordisk A/S | Phase 3 |
| Completed | Comparison of a Blood Clotting Drug (Recombinant Factor XIII) Produced by Two Different Manufacturers in Healt NCT01082406 | Novo Nordisk A/S | Phase 1 |
| Completed | Safety and Efficacy of Turoctocog Alfa (N8) in Prevention and On-demand Treatment of Bleeding Episodes in Subj NCT00984126 | Novo Nordisk A/S | Phase 3 |
| Completed | Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficien NCT00978380 | Novo Nordisk A/S | Phase 3 |
| Completed | Safety and Efficacy of 3 Different Doses of Long Acting Factor VII in Haemophilia A or B Patients With Inhibit NCT00951405 | Novo Nordisk A/S | Phase 2 |
| Completed | Safety of 40K Pegylated Recombinant Factor IX in Non-Bleeding Patients With Haemophilia B NCT00956345 | Novo Nordisk A/S | Phase 1 |
| Completed | A Single Dose Trial Investigating Safety and Local Tolerability of Ascending Doses of Long Acting Activated Re NCT00951873 | Novo Nordisk A/S | Phase 1 |
| Completed | Safety and Mode of Action of a Single Dose and Multiple Doses of Long Acting Activated Recombinant Human Facto NCT00922792 | Novo Nordisk A/S | Phase 1 |
| Completed | PROPACT: Retrospective Prophylaxis Patient Case Collection NCT00882778 | Novo Nordisk A/S | — |
| Completed | Safety and Efficacy of Turoctocog Alfa in Haemophilia A Subjects NCT00840086 | Novo Nordisk A/S | Phase 3 |
| Completed | Comparison of the Action of Drugs in the Body and Safety of N8 and Advate® in Haemophilia A Subjects NCT00837356 | Novo Nordisk A/S | Phase 1 |
| Completed | Safety, Tolerability and Pharmacokinetics of NN1731 in Healthy Volunteers NCT00822185 | Novo Nordisk A/S | Phase 1 |
| Completed | Evaluation of Recombinant Factor XIII for Prevention of Bleeding in Patients With FXIII Inherited Deficiency NCT00713648 | Novo Nordisk A/S | Phase 3 |
| Completed | Observational Study on the Efficacy and Safety of NovoSeven® During "Real-life" Usage in Germany NCT00697320 | Novo Nordisk A/S | — |
| Completed | Observational Patient Diary Study of Treatment Doses for Patients With Haemophilia With Inhibitors to Factors NCT00710619 | Novo Nordisk A/S | — |
| Completed | Observational Registry of NovoSeven® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A and NCT00703911 | Novo Nordisk A/S | — |
| Completed | Post-marketing Safety Surveillance of NovoSeven® in Patients With Haemophilia and Inhibitors by Means of the U NCT00853086 | Novo Nordisk A/S | — |
| Completed | Haemophilia Patients With Inhibitors Being Treated for Acute Joint Bleeds NCT00486278 | Novo Nordisk A/S | Phase 2 |
| Completed | Bioequivalence of NovoSeven® and a NovoSeven® Formulation Stable at Room Temperature in Healthy Male Subjects NCT01561417 | Novo Nordisk A/S | Phase 1 |
| Completed | Intra-subject Variability Following Administrations of Activated Recombinant Human Factor VII in Haemophilia P NCT01562457 | Novo Nordisk A/S | Phase 1 |
| Completed | Prediction of the Efficacy of Activated Recombinant Human Factor VII in Adult Congenital Haemophilia A or B Pa NCT01561924 | Novo Nordisk A/S | Phase 1 |
| Completed | Treatment of Congenital Factor VII Deficiency NCT01779921 | Novo Nordisk A/S | — |
| Completed | Dose Response to Recombinant Factor VIIa When Administered for Bleed NCT00104455 | Novo Nordisk A/S | Phase 1 |
| Completed | Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia NCT00108758 | Novo Nordisk A/S | Phase 2 |
| Completed | Observational Registry of the Treatment of Glanzmann's Thrombasthenia NCT01476423 | Novo Nordisk A/S | — |
| Completed | Safety and Pharmacokinetics of Recombinant Factor XIII Administration in Healthy Volunteers NCT01848002 | Novo Nordisk A/S | Phase 1 |
| Completed | Safety and Pharmacokinetics of Recombinant Factor XIII in Patients With Congenital Factor Xlll Deficiency NCT00056589 | Novo Nordisk A/S | Phase 1 |
| Completed | Safety and Pharmacokinetics of Recombinant Factor XIII in Healthy Volunteers NCT01847989 | Novo Nordisk A/S | Phase 1 |
| Completed | High Dose of Activated Recombinant Human Factor VII for Treatment of Mild/Moderate Joint Bleeds in Haemophilia NCT00571584 | Novo Nordisk A/S | Phase 4 |
| Completed | Pharmacokinetics of Single Bolus Dose of NovoSeven® in Paediatric and Adult Patients With Haemophilia A or B i NCT01562587 | Novo Nordisk A/S | Phase 1 |
| Completed | Safety and Tolerability of Intravenous Doses of Activated Recombinant Human Factor VII in Healthy Volunteers NCT01563471 | Novo Nordisk A/S | Phase 1 |
| Completed | Trial of NovoSeven® in Haemophilia - Joint Bleeds NCT00108797 | Novo Nordisk A/S | Phase 4 |
| Completed | Non-Interventional Study of NovoSeven® Used in Patients With Haemophilia A and B With Inhibitors Under Normal NCT01579955 | Novo Nordisk A/S | — |
| Completed | Non-Interventional Study of NovoSeven® Used in Patients With Haemophilia A and B With Inhibitors When Undergoi NCT01579968 | Novo Nordisk A/S | — |
| Completed | Non-Interventional Study of NovoSeven® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A an NCT01586936 | Novo Nordisk A/S | — |
| Completed | Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During a NCT01561391 | Novo Nordisk A/S | Phase 4 |